By CapitalSnitch Research Desk · updated Oct 11, 2026 · data from SEC filings and official Congress disclosures
Over the last 12 months, four Relmada Therapeutics, Inc. company insiders bought into shares at market prices, about $4 million in total, and none of them sold.
Shenouda Maged (CFO) made the biggest buy, worth around $1.1 million. Notably, at least one C-suite executive was among the buyers.
On the institutional side, 126 funds reported holding RLMD at the end of Q2 2026, and more funds bought than sold. Looking at the quarterly pattern: Last full quarter: net buying by insiders. Insiders bought in 4 of the last 7 full quarters.
Are insiders buying or selling RLMD stock?
In the last 12 months Relmada Therapeutics, Inc. insiders made open-market purchases worth about $4 million and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
When was the last insider trade in RLMD?
The most recent open-market insider trade in RLMD was filed on 2026-09-11.
How many institutions own RLMD?
126 investment managers reported holding RLMD in SEC Form 13F filings for Q2 2026.
Has any member of Congress traded RLMD?
No congressional trades in RLMD were reported in the past two years. The full list is free on CapitalSnitch.
Free weekly email: the week's biggest insider buys and Congress trades, every Monday. No spam, one-click unsubscribe.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1).
Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).